Pro-Dex AI Stock Analysis
Want to see PDEX full AI Analyst Report?
Pro-Dex (PDEX) AI Stock Analysis
Pro-Dex
(NASDAQ:PDEX)
The score is primarily supported by materially improved financial performance (strong TTM profitability, ROE, and improving leverage). This is tempered by weak near-term technicals (below key moving averages with negative MACD and low RSI) and only moderately positive corporate developments, while valuation appears reasonable based on the current P/E and no dividend yield support.
Pro-Dex Key Performance Indicators (KPIs)
Revenue by SegmentHighlights revenue from different business segments, revealing which areas are driving growth and which may need strategic adjustments.
Pro-Dex’s growth has become increasingly concentrated in Orthopedic, which has established a much higher run rate since late 2024 and continues to expand despite modest quarterly pullbacks. CMF remains a volatile but relatively stable secondary contributor, while Thoracic has lost much of its earlier scale and has not regained consistent momentum. This mix shift strengthens near-term growth but increases reliance on sustained orthopedic demand and customer programs.
Pro-Dex (PDEX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $198.18M
- Dividend Yield
- ―
- Average Volume (3M)
- 54.31K
- Price to Earnings (P/E)
- 16.6
- Beta (1Y)
- 0.38
- Revenue Growth
- 13.31%
- EPS Growth
- 9.26%
- Country
- US
- Employees
- 204
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Pro-Dex Business Overview & Revenue Model
Company Description
Pro-Dex, Inc. focuses on the development and manufacturing of advanced motorized surgical instruments. These sophisticated tools are supplied globally to original equipment manufacturers (OEMs) in the medical device sector. Their product portfolio fe...
How the Company Makes Money
Pro-Dex primarily makes money by providing contract manufacturing and engineering services to medical device original equipment manufacturers (OEMs). Revenue is generated through (1) manufacturing and assembly of powered surgical instruments and rela...
Pro-Dex Financial Statement Overview
Summary
Strong TTM profitability and scale-up (revenue ~$79.6M, ~32% gross margin, ~15% operating/net margins) with solid ROE (~26%) and improving leverage (debt-to-equity ~0.38). Offsetting this, cash flow has been historically volatile and cash conversion is not consistently >1x net income, indicating working-capital timing and some margin volatility risk.
Income Statement
84Very PositiveBalance Sheet
78PositiveCash Flow
73Positive| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.58M | 77.55M | 66.59M | 53.84M | 46.09M | 42.04M |
| Gross Profit | 25.82M | 24.34M | 19.51M | 14.55M | 12.75M | 13.13M |
| EBITDA | 17.14M | 14.38M | 14.13M | 4.35M | 10.82M | 6.88M |
| Net Income | 12.03M | 13.66M | 8.98M | 2.13M | 7.07M | 4.57M |
Balance Sheet | ||||||
| Total Assets | 76.59M | 74.51M | 61.19M | 52.48M | 51.82M | 49.09M |
| Cash, Cash Equivalents and Short-Term Investments | 12.99M | 9.34M | 7.16M | 6.85M | 4.07M | 1.60M |
| Total Debt | 18.98M | 18.10M | 16.58M | 13.55M | 14.79M | 15.97M |
| Total Liabilities | 27.24M | 26.88M | 24.56M | 21.61M | 20.23M | 23.66M |
| Stockholders Equity | 49.35M | 47.63M | 36.63M | 30.87M | 31.59M | 25.43M |
Cash Flow | ||||||
| Free Cash Flow | 10.82M | 6.76M | -2.93M | 5.22M | 4.49M | -2.52M |
| Operating Cash Flow | 11.42M | 7.24M | -1.68M | 6.20M | 5.46M | -847.00K |
| Investing Cash Flow | 3.67M | 3.91M | -238.00K | -2.23M | -885.00K | -1.24M |
| Financing Cash Flow | -10.52M | -3.38M | -292.00K | -4.27M | -2.49M | -790.00K |
Pro-Dex Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDEX, the sentiment is Negative. The current price of 61.93 is below the 20-day moving average (MA) of 63.39, below the 50-day MA of 64.77, and above the 200-day MA of 58.01, indicating a neutral trend. The MACD of 0.66 indicates Negative momentum. The RSI at 45.92 is Neutral, neither overbought nor oversold. The STOCH value of 35.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PDEX.
Pro-Dex Risk Analysis
Pro-Dex disclosed 24 risk factors in its most recent earnings report. Pro-Dex reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksPro-Dex Peers Comparison
Overall Rating
UTMD73Outperform
PDEX68Neutral
KRMD57Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $205.22M | 21.43 | 8.78% | 1.72% | -9.62% | -5.65% | |
| 68Neutral | $198.18M | 16.56 | 26.18% | ― | 13.31% | 9.26% | |
| 57Neutral | $151.38M | -195.48 | 0.00% | ― | 18.43% | 78.07% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PDEX | Pro-dex | 61.93 | 33.02 | 114.22% | |
| UTMD | Utah Medical Products | 72.02 | 19.14 | 36.19% | |
| MBOT | Microbot Medical | 0.69 | -1.23 | -64.11% | |
| KRMD | Repro-Med Systems, Inc. | 3.49 | -0.86 | -19.77% | |
| ZJYL | Jin Medical International Ltd. | 3.38 | -1.87 | -35.69% |
Pro-Dex Corporate Events
Pro-Dex expands Costa Mesa industrial footprint with new lease
PositiveOn October 26, 2026, Advanced Precision Machining renewed three leases for about 2,500 square feet of office and industrial space in Costa Mesa, extending their terms to September 30, 2030 and locking in base rent increases of 4.0% to 6.6% starting F...
Pro-Dex Extends Irvine Headquarters Lease Through 2030
PositiveOn September 16, 2026, Pro-Dex entered into a Third Amendment to its long-standing lease for its Irvine headquarters and manufacturing facility, effective August 18, 2026, extending the lease term to September 30, 2030. The amendment introduces 3.5%...
Pro-Dex Awards Executive Bonuses After Strong Fiscal 2026
PositiveOn August 26, 2026, Pro-Dex’s compensation committee approved discretionary cash bonuses for Chief Executive Officer Richard L. Van Kirk and Chief Financial Officer Alisha K. Charlton, to be paid in the next bi-weekly pay period with a pay date of Se...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
